FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915698847> ?p ?o ?g. }

• W2915698847 endingPage "444" @default.
• W2915698847 startingPage "426" @default.
• W2915698847 abstract "PurposeFormulations of ω (OM)-3 with adequate bioavailability in the low-fat fed state are advantageous in patients with severe hypertriglyceridemia (HTG), as these patients are advised to adhere to a low-fat diet. The OM3-containing prescription drugs approved by the US Food and Drug administration (FDA) provide OM3 in either ethyl ester (EE) or free fatty acid (FFA) forms. The OM3 FFA form and formulations with micelle-forming ability have shown improved bioavailability versus the EE form. OM3 phospholipid (PL)/FFA, a krill oil–derived OM3 mixture containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present as PL esters and FFA, is being developed for the treatment of severe HTG. Both forms of OM3 in OM3-PL/FFA are believed to be digested and absorbed more efficiently as compared to OM3 in EE. This hypothesis was tested by comparing the relative bioavailabilities of EPA and DHA from a single 4-g dose administration of OM3-PL/FFA to those the FDA-approved HTG drug OM3-EE in the fed (high-fat meal) and fasted states. The effects of food on the bioavailability of both drugs were also tested.MethodsThis open-label, randomized, 4-way crossover bioavailability study was conducted in 56 healthy adults who were randomly assigned to receive a single 4-g dose of OM3-PL/FFA or OM3-EE in the fasted and fed (high-fat meal) states. The relative bioavailabilities of EPA and DHA were compared between the 2 formulations using pharmacokinetic analysis.FindingsIn the fasted state, the AUC0–72 and Cmax of EPA + DHA were 5- and 2.7-fold higher, respectively, with OM3-PL/FFA versus OM3-EE. These values were 3- and 4-fold lower in the fed state with OM3-PL/FFA versus OM3-EE. On administration of OM3-EE, the AUC0–72 and Cmax of EPA + DHA were 25- and 11-fold higher, respectively, in the fed versus the fasted state. A much lower increase (1.7-fold) in the AUC0–72 of EPA + DHA was observed on administration of OM3-PL/FFA in the fed versus the fasted state, with similar Cmax values.ImplicationsThese results demonstrate that the bioavailabilities of EPA and DHA with OM3-PL/FFA, as FFA and conjugated to PL, are far less affected by the fat content of a meal as compared to the EPA and DHA EEs in OM3-EE. These findings suggest a potential clinical advantage with OM3-PL/FFA, since patients with HTG are advised to follow a fat-restricted diet." @default.
• W2915698847 created "2019-03-02" @default.
• W2915698847 creator A5002781938 @default.
• W2915698847 creator A5032517154 @default.
• W2915698847 creator A5035358062 @default.
• W2915698847 creator A5070664432 @default.
• W2915698847 creator A5084185935 @default.
• W2915698847 creator A5086371982 @default.
• W2915698847 date "2019-03-01" @default.
• W2915698847 modified "2023-10-02" @default.
• W2915698847 title "A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States" @default.
• W2915698847 cites W1456970633 @default.
• W2915698847 cites W1512707865 @default.
• W2915698847 cites W1967398549 @default.
• W2915698847 cites W1985217984 @default.
• W2915698847 cites W2007855541 @default.
• W2915698847 cites W2036747551 @default.
• W2915698847 cites W2048222715 @default.
• W2915698847 cites W2048382309 @default.
• W2915698847 cites W2057006290 @default.
• W2915698847 cites W2064358352 @default.
• W2915698847 cites W2076525475 @default.
• W2915698847 cites W2101332425 @default.
• W2915698847 cites W2101925152 @default.
• W2915698847 cites W2102189298 @default.
• W2915698847 cites W2106620061 @default.
• W2915698847 cites W2111556368 @default.
• W2915698847 cites W2120512966 @default.
• W2915698847 cites W2142533350 @default.
• W2915698847 cites W2155653553 @default.
• W2915698847 cites W2156968573 @default.
• W2915698847 cites W2582578406 @default.
• W2915698847 cites W2586679362 @default.
• W2915698847 cites W2586964582 @default.
• W2915698847 doi "https://doi.org/10.1016/j.clinthera.2019.01.017" @default.
• W2915698847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30799231" @default.
• W2915698847 hasPublicationYear "2019" @default.
• W2915698847 type Work @default.
• W2915698847 sameAs 2915698847 @default.
• W2915698847 citedByCount "15" @default.
• W2915698847 countsByYear W29156988472019 @default.
• W2915698847 countsByYear W29156988472020 @default.
• W2915698847 countsByYear W29156988472021 @default.
• W2915698847 countsByYear W29156988472022 @default.
• W2915698847 countsByYear W29156988472023 @default.
• W2915698847 crossrefType "journal-article" @default.
• W2915698847 hasAuthorship W2915698847A5002781938 @default.
• W2915698847 hasAuthorship W2915698847A5032517154 @default.
• W2915698847 hasAuthorship W2915698847A5035358062 @default.
• W2915698847 hasAuthorship W2915698847A5070664432 @default.
• W2915698847 hasAuthorship W2915698847A5084185935 @default.
• W2915698847 hasAuthorship W2915698847A5086371982 @default.
• W2915698847 hasBestOaLocation W29156988471 @default.
• W2915698847 hasConcept C112705442 @default.
• W2915698847 hasConcept C126322002 @default.
• W2915698847 hasConcept C142724271 @default.
• W2915698847 hasConcept C181389837 @default.
• W2915698847 hasConcept C185592680 @default.
• W2915698847 hasConcept C19038510 @default.
• W2915698847 hasConcept C204787440 @default.
• W2915698847 hasConcept C22979827 @default.
• W2915698847 hasConcept C27081682 @default.
• W2915698847 hasConcept C2776091944 @default.
• W2915698847 hasConcept C2777171753 @default.
• W2915698847 hasConcept C2778345441 @default.
• W2915698847 hasConcept C31903555 @default.
• W2915698847 hasConcept C543025807 @default.
• W2915698847 hasConcept C55493867 @default.
• W2915698847 hasConcept C71924100 @default.
• W2915698847 hasConcept C87813604 @default.
• W2915698847 hasConcept C98274493 @default.
• W2915698847 hasConceptScore W2915698847C112705442 @default.
• W2915698847 hasConceptScore W2915698847C126322002 @default.
• W2915698847 hasConceptScore W2915698847C142724271 @default.
• W2915698847 hasConceptScore W2915698847C181389837 @default.
• W2915698847 hasConceptScore W2915698847C185592680 @default.
• W2915698847 hasConceptScore W2915698847C19038510 @default.
• W2915698847 hasConceptScore W2915698847C204787440 @default.
• W2915698847 hasConceptScore W2915698847C22979827 @default.
• W2915698847 hasConceptScore W2915698847C27081682 @default.
• W2915698847 hasConceptScore W2915698847C2776091944 @default.
• W2915698847 hasConceptScore W2915698847C2777171753 @default.
• W2915698847 hasConceptScore W2915698847C2778345441 @default.
• W2915698847 hasConceptScore W2915698847C31903555 @default.
• W2915698847 hasConceptScore W2915698847C543025807 @default.
• W2915698847 hasConceptScore W2915698847C55493867 @default.
• W2915698847 hasConceptScore W2915698847C71924100 @default.
• W2915698847 hasConceptScore W2915698847C87813604 @default.
• W2915698847 hasConceptScore W2915698847C98274493 @default.
• W2915698847 hasFunder F4320307105 @default.
• W2915698847 hasFunder F4320307781 @default.
• W2915698847 hasFunder F4320311600 @default.
• W2915698847 hasIssue "3" @default.
• W2915698847 hasLocation W29156988471 @default.
• W2915698847 hasLocation W29156988472 @default.
• W2915698847 hasOpenAccess W2915698847 @default.
• W2915698847 hasPrimaryLocation W29156988471 @default.
• W2915698847 hasRelatedWork W1969574919 @default.

• next